NCT06747429Recruiting
High Fat Diet for Cardiac Metabolic Reprogramming
Cardiac Metabolic Reprogramming by a Nutritional Intervention: the High Fat Diet for Heart Failure (HF4HF) Study, a proof-of Concept Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
Heart failure (HF) continues to be a leading cause of morbidity and mortality worldwide, despite advances in treatment. HF is often characterized by an altered metabolism in the heart, where glucose is favored over fatty acids as the primary energy substrate. This metabolic shift has been hypothesized to contribute to disease progression. Previous studies using animal models have demonstrated that restoring fatty acid metabolism through dietary intervention can reverse the adverse metabolic effects and improve heart function. A transgenic murine model with mitochondrial defects, for instance, exhibited improved cardiac function after an HFD intervention. These findings were reinforced by a translational pig model of non-ischemic DCM, where a high-fat diet significantly improved LVEF compared to a standard diet. Building upon these promising preclinical results, a small-scale human study showed that lipid infusion, rather than glucose, improved cardiac function in HF patients. However, the long-term benefits of a HFD in heart failure patients have yet to be thoroughly explored. The HF4HF trial aims to fill this gap by evaluating the effects of an HFD over a two-month period in patients with non-ischemic DCM and reduced LVEF. The "High Fat Diet for Heart Failure" (HF4HF) study is a proof-of-concept randomized controlled trial designed to investigate the efficacy of a high-fat diet (HFD) as a therapeutic intervention in patients with non-ischemic dilated cardiomyopathy (DCM) and reduced left ventricular ejection fraction (LVEF). The study hypothesizes that cardiac metabolic reprogramming, achieved through a controlled nutritional intervention involving an HFD, can enhance systolic function, myocardial energetics, and overall heart function in heart failure (HF) patients. Cofunded by the European Commission and national entities, the trial is spearheaded by a consortium of cardiovascular research centers across four countries: Spain, Italy, France, and Romania.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 18 Dec 2024
- Start date
- 15 Jan 2026
- Primary completion date
- Jun 2026
- Lead sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- Diseases
- Heart failure
- NCT number
- NCT06747429
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 15 Jan 2026 to the primary completion date, Jun 2026
- 5 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior diagnosis of ischemic DCM.
- Prior diagnosis of established atherosclerotic cardiovascular disease (angina/myocardial infarction, transient ischemic attack/stroke, lower limb ischemia or at any other peripheral level).
- Changes in HF therapies within the last 3 months.
- HF decompensation within the previous 3 months, including HF hospitalization or the need of ambulatory intravenous diuretic or inotropic treatment such as levosimendan.
- Liver and biliary diseases, including prior diagnosis of non-alcoholic fatty liver disease and unoperated cholelithiasis.
- Prior episodes of acute pancreatitis or chronic pancreatitis.
- Prior fish or nut allergy.
Other illness
- Any contraindication for CMR:
- Severe claustrophobia. Any device which is known to threaten or pose hazard in all MR environments. //www.mrisafety.com/ Patients with implanted biomedical devices (cardiac artefacts): pacemakers, cardiac defibrillators or cardiac resynchronization therapy.
Lab values
- Uncontrolled dyslipidemia, defined as LDL-cholesterol \>160 mg/dL and/or triglycerides \>200 mg/dL, despite treatment.
Other
- Life expectancy less than 12 months.
- Pregnancy or planned pregnancy for the next 4 months.
- Current lactation.
- Patients participating in other randomized clinical trial.
- Impossibility to consent or undergo study follow-up
Who the study is looking for
- Patients of both sexes and ≥18 years old
- Patients diagnosed with HF secondary to non-ischemic DCM, according to ESC guidelines definition,1 with or without a known genetic basis.
- LVEF ≤49% according to the baseline CMR.
- Optimized HF guideline-directed medical therapy for at least 3 months prior to inclusion.
- Patients who have provided informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro (IIS), Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Hôpital Européen Georges Pompidou, INSERM Coordinator of this site? Confirm its status | Paris | France | Not yet recruiting |
| University of Florence, Clinical and Experimental Medicine, Unit of Clinical Nutrition, Coordinator of this site? Confirm its status | Florence | Italy | Not yet recruiting |
| University of Medicine and Pharmacy "Carol Davila", Bucharest, Coordinator of this site? Confirm its status | Bucharest | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.